Acetazolamide ( DrugBank: Acetazolamide )


6 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎1
90網膜色素変性症1
115遺伝性周期性四肢麻痺1
155ランドウ・クレフナー症候群1
225先天性腎性尿崩症1
230肺胞低換気症候群1

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02466074
(ClinicalTrials.gov)
August 17, 20163/6/2015Augmenting Cerebral Blood Flow to Treat Established Multiple SclerosisAugmenting Cerebral Blood Flow to Treat Established Multiple SclerosisMultiple SclerosisDrug: Acetazolamide;Drug: PlaceboThe University of Texas Health Science Center, HoustonNULLActive, not recruiting18 Years55 YearsAll60Phase 2United States

90. 網膜色素変性症


臨床試験数 : 130 薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000022686
2016/07/0101/07/2016The Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis PigmentosaThe Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa - The Clinical Efficacy in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa retinitis pigmentosa1% dorzolamide eye drop three times daily in each eye
0.1% betamethasone sodium phosphate eye drop three times daily in each eye
oral 250mg acetazolamide two tablets daily
40mg triamcinolone acetonide into the sub-Tenon capsule
Kyushu University HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female40Not applicableJapan

115. 遺伝性周期性四肢麻痺


臨床試験数 : 1 薬物数 : 2 - (DrugBank : 2) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 7
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00839501
(ClinicalTrials.gov)
December 20085/2/2009Effect of Potassium and Acetazolamide on People With Andersen-Tawil SyndromeTherapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil SyndromeAndersen-Tawil SyndromeDietary Supplement: Potassium;Drug: AcetazolamideUniversity of RochesterOffice of Rare Diseases (ORD);Rare Diseases Clinical Research Network;National Institute of Neurological Disorders and Stroke (NINDS)Terminated10 YearsN/ABoth3Phase 1United States;United Kingdom

155. ランドウ・クレフナー症候群


臨床試験数 : 1 薬物数 : 2 - (DrugBank : 2) / 標的遺伝子数 : 29 - 標的パスウェイ数 : 14
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02904265
(ClinicalTrials.gov)
September 201613/9/2016Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner SyndromeNon-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS)Landau-Kleffner Syndrome;Status Epilepticus, ElectrographicDrug: Diazepam;Drug: AcetazolamideMayo ClinicNULLTerminated3 Years12 YearsAll3Phase 2/Phase 3United States

225. 先天性腎性尿崩症


臨床試験数 : 15 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 64
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-005970-41-NL
(EUCTR)
27/02/201208/02/2012The effect of the drug acetazolamide on excessive urine production due to a diminished concentrating ability of the kidney as a result of the use of lithium in patients with an affective disorder: a pilot studyThe effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study lithium-induced nephrogenic diabetes insipidus
MedDRA version: 14.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Acetazolamide Sandoz 250
Other descriptive name: ACETAZOLAMIDE
Radboud University Nijmegen Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands

230. 肺胞低換気症候群


臨床試験数 : 8 薬物数 : 11 - (DrugBank : 5) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 28
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01499485
(ClinicalTrials.gov)
November 201120/12/2011Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.Effects of Acetazolamide on the Duration of Mechanical Ventilation in Patients With Metabolic Alkalosis. Phase III Multicenter Double-blinded Clinical Trial.Pulmonary Disease, Chronic Obstructive;Obesity Hypoventilation Syndrome;Metabolic AlkalosisDrug: Acetazolamide;Drug: PlaceboHospital Son LlatzerNULLCompleted18 YearsN/ABoth140Phase 3Spain